Gene · 11047
ADRM1: ADRM1 26S proteasome ubiquitin receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRM1: ADRM1 26S proteasome ubiquitin receptor. Genes, record 11047. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/11047
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16186 | Proteasomal ubiquitin receptor ADRM1 | 407 | 21 | Ensembl, GeneID, HGNC |
Source UniProt
Patents43
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| EP 4650780 A2 | 2025-11-19 | 1422 | Q16186 | Espacenet |
| KR 1020250153662 A | 2025-10-27 | 3 | Q16186 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 1422 | Q16186 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3156 | Q16186 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3157 | Q16186 | Espacenet |
| US 11708610 B2 | 2023-07-25 | 1014 | Q16186 | Espacenet |
| US 11702402 B2 | 2023-07-18 | 4 | Q16186 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3156 | Q16186 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3157 | Q16186 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 106127 | Q16186 | Espacenet |
1 to 10 of 43
See all 43 patentsDrugs6
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BORTEZOMIB | CHEMBL325041 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| BORTEZOMIB D-MANNITOL | CHEMBL5315122 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| CARFILZOMIB | CHEMBL451887 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB | CHEMBL2141296 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| IXAZOMIB CITRATE | CHEMBL3545432 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
| OPROZOMIB | CHEMBL2103884 | 26S proteasome inhibitor | INHIBITOR | ChEMBL |
Trials1,229
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07605416 | CARFILZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07601100 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07600151 | BORTEZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07513129 | BORTEZOMIB | PHASE1 | ClinicalTrials.gov | |
| NCT07479979 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07464210 | BORTEZOMIB | PHASE2 | ClinicalTrials.gov | |
| NCT07463807 | CARFILZOMIB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07428369 | BORTEZOMIB | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | BORTEZOMIB | PHASE3 | ClinicalTrials.gov | |
| NCT07391657 | CARFILZOMIB | PHASE3 | ClinicalTrials.gov |
1 to 10 of 1,229
See all 1,229 trialsNIH grants502
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRM1 papers | Newest fiscal year |
|---|---|---|---|
| ZIABC011490 | Maintaining cell health by targeted protein degradation | 11 | 2025 |
| P30CA006973 | Regional Oncology Research Center | 6 | 2025 |
| P50CA098252 | SPORE in Cervical Cancer | 6 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 4 | 2025 |
| P30CA042014 | Cancer Center Support Grant | 3 | 2025 |
| R01GM065334 | Solution structure and dynamics of polyubiquitin chains | 3 | 2025 |
| P01CA155258 | Integrative Oncogenomics of Multiple Myeloma | 2 | 2025 |
| P01DA009158 | Endocannabinoid Active Sites as Therapeutic Targets | 2 | 2025 |
| P20GM103418 | Kansas IDeA Network of Biomedical Research Excellence 5 | 2 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 2 | 2025 |
1 to 10 of 502Source NIH's project files
See all 502 nih grantsPapers608
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| circZNF148 Drives Glucose Metabolism Reprogramming to Enhance Metastasis and Immune Evasion via HK1 Stabilization in Triple-Negative Breast Cancer. | Adv Sci (Weinh) | 2026 | 42565531 | PubTator, text mining | PubMed |
| Ubiquitin-mediated degradation of RPN13 promotes porcine sperm capacitation and sperm-zona pellucida binding. | Zygote | 2026 | 42554175 | PubTator, text mining | PubMed |
| Substrate biasing in UCHL5 proteoforms. | bioRxiv | 2026 | 42523381 | PubTator, text mining | PubMed |
| Structures of dynamic interactors at native proteasomes by PhIX-MS and cryo-electron microscopy. | Mol Cell | 2026 | 42476128 | PubTator, text mining | PubMed |
| CDW19S coordinates phasic end processing via distinct enzymatic activities. | Nucleic Acids Res | 2026 | 42406631 | PubTator, text mining | PubMed |
| M6A-modified circArhgap26 attenuates cardiac ischemia‒reperfusion injury by suppressing plakophilin-1 palmitoylation. | Signal Transduct Target Ther | 2026 | 41844577 | PubTator, text mining | PubMed |
| Current research on adhesion regulating molecule 1: A Review. | Biochem Biophys Res Commun | 2026 | 41825124 | PubTator, text mining | PubMed |
| Repeat-rich RNA guides repetitive genomic elements into biomolecular condensates for heterochromatin organization and muscle integrity. | Nucleic Acids Res | 2026 | 41797541 | PubTator, text mining | PubMed |
| Systematic analysis of functional genetic and epigenetic variants in colorectal cancer. | Sci Adv | 2026 | 41719390 | PubTator, text mining | PubMed |
| Comprehensive analysis and experimental confirmation identify ADRM1 plays an oncogenic and immunosuppression role in KIRC. | Biochem Biophys Res Commun | 2026 | 41406707 | PubTator, text mining | PubMed |
1 to 10 of 608
See all 608 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/11047
GET https://conductscience.org/api/genes/v1/11047/patents?page=2